Contents
Key Facts — AOD-9604
- AOD-9604 has a molecular weight of approximately 1815.12 Da and consists of a modified fragment of human growth hormone (hGH) spanning amino acids 176–191
- The peptide’s full name is Anti-Obesity Drug 9604; it was developed by Monash University in Melbourne, Australia
- A 12-week placebo-controlled clinical trial published in Obesity Research found that subjects receiving 1mg/day of AOD-9604 lost significantly more body fat than those on placebo, without affecting blood glucose or IGF-1 levels
- AOD-9604 does not bind to the growth hormone receptor and does not stimulate systemic IGF-1 production, distinguishing it from full-length hGH
- The FDA granted AOD-9604 GRAS (Generally Recognized As Safe) status in 2014, making it one of the few peptides to have achieved this designation
- Typical reconstituted AOD-9604 vials contain 2mg–5mg of lyophilized peptide and are stored refrigerated at 2–8°C after reconstitution
Key Takeaways
- The evidence-supported daily dose is 300mcg–500mcg for general research purposes, with 1mg/day reflecting the most studied clinical dose
- AOD-9604 works by mimicking the lipolytic (fat-burning) region of hGH without triggering growth-promoting or blood sugar-elevating effects
- Morning administration on an empty stomach — ideally 30 minutes before food or exercise — produces the most consistent outcomes in clinical and research settings
- AOD-9604 is not anabolic and does not suppress natural hormone production, making it a distinct category of peptide compared to GHRPs or SARMs
- Combining AOD-9604 with a caloric deficit and resistance training produces noticeably better fat loss outcomes than the peptide alone
AOD-9604 dosage precision matters more than it does with many other peptides — use the wrong amount and you’ll either see no effect or leave measurable results on the table. This guide covers the clinically studied dose ranges, administration protocols, reconstitution steps, and what the research actually shows about this hGH-derived fat loss peptide. Whether you’re looking at a short cycle or a structured 12-week protocol, the numbers here are drawn directly from published trials and peer-reviewed pharmacological data. Use the free AOD-9604 dosage calculator on PepFormula to get your exact dose.
What is AOD-9604?
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone, specifically spanning amino acids 176 to 191. It was developed in the 1990s at Monash University in Australia with the explicit goal of isolating the fat-metabolizing properties of hGH without replicating its anabolic or blood glucose-altering effects.
The name stands for Anti-Obesity Drug 9604, which reflects its origins as a pharmaceutical candidate for obesity treatment rather than a performance enhancement compound. Researchers identified early on that the full hGH molecule produced fat loss partly through this specific terminal region, and that isolating this fragment retained lipolytic activity while stripping out IGF-1 stimulation.
Structurally, AOD-9604 is a 16-amino acid peptide with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a disulfide bond between the two cysteine residues. This structural feature is central to its biological stability and receptor interaction.
AOD-9604 underwent multiple human clinical trials between 2001 and 2007 under the pharmaceutical name AOdia, developed by Metabolic Pharmaceuticals. Although it did not achieve regulatory approval as an oral obesity drug — partly due to modest effect sizes when taken orally at high doses — the injectable form demonstrated a much more favorable pharmacokinetic profile and is the basis for current research use.
For a broader understanding of how synthetic peptides like this are developed and categorized, see the guide on what are peptides on PepFormula.
How Does AOD-9604 Work?
AOD-9604 stimulates fat breakdown (lipolysis) and inhibits fat accumulation (lipogenesis) through mechanisms that mirror the fat-metabolizing actions of endogenous growth hormone. It does this without activating the growth hormone receptor itself, which is what separates it from full-length hGH.
The peptide interacts with fat cell receptors — particularly beta-3 adrenergic receptors — to trigger the mobilization of stored triglycerides. Once mobilized, these fatty acids enter circulation and become available as fuel. This is a direct, receptor-mediated effect rather than a downstream consequence of IGF-1 elevation.
Importantly, AOD-9604 does not raise serum IGF-1 levels. In clinical trials, subjects receiving 1mg/day for 12 weeks showed no statistically significant changes in IGF-1, insulin sensitivity, or fasting blood glucose compared to placebo. This is a pharmacologically significant distinction: full-length hGH reliably elevates IGF-1 and can cause insulin resistance at therapeutic doses, while AOD-9604 avoids both of these issues.
AOD-9604 also appears to have an inhibitory effect on lipogenesis — the conversion of carbohydrates and other substrates into stored fat. Animal studies have demonstrated that AOD-9604 reduces fat accumulation in high-fat diet models, not merely through increased lipolysis but through a dual mechanism that limits new fat storage simultaneously.
There is also early-stage research suggesting AOD-9604 may support cartilage and bone repair through mechanisms unrelated to growth hormone. These findings are preliminary but have generated interest in combining AOD-9604 with tissue-repair peptides. For comparison with other recovery-focused compounds, the BPC-157 dosage guide provides detailed context on a frequently paired peptide.
AOD-9604 Benefits
AOD-9604 delivers measurable fat loss through a direct lipolytic mechanism, without the hormonal side effects associated with growth hormone therapy. The evidence for its fat loss effects in humans comes from randomized, placebo-controlled trials — a higher standard of evidence than most research peptides have achieved.
Fat Loss The pivotal 12-week trial published in Obesity Research (2001) showed that subjects receiving 1mg/day of oral AOD-9604 lost significantly more body fat than placebo, with the effect concentrated in visceral and abdominal fat depots. Injectable AOD-9604 is expected to be more bioavailable than the oral formulation used in that trial, which is why current research protocols typically use 300mcg–1mg via subcutaneous injection.
No IGF-1 Elevation Because AOD-9604 does not bind the growth hormone receptor, it produces no increase in circulating IGF-1. This means none of the growth-promoting, proliferative risks associated with exogenous hGH use apply to this peptide — a meaningful safety distinction for longer-term use.
Insulin Sensitivity Preservation Clinical data confirmed that AOD-9604 does not impair glucose tolerance or reduce insulin sensitivity. Subjects maintained normal metabolic profiles throughout the 12-week trial period. This makes it pharmacologically compatible with people who are already managing metabolic dysfunction.
Potential Cartilage and Bone Support Preclinical data from Obesity Research and subsequent animal studies suggest AOD-9604 may have regenerative effects on cartilage tissue. This mechanism is thought to be entirely separate from its fat loss pathway and has not been confirmed in human trials, but it contributes to its use alongside peptides like BPC-157 in combined protocols.
Body Composition Without Muscle Loss AOD-9604 targets fat tissue selectively. Unlike extreme caloric restriction, which degrades lean muscle mass alongside fat, AOD-9604’s mechanism acts specifically on adipocytes, supporting body composition improvements without catabolic effects on muscle.
If you’re researching the broader landscape of peptides for fat loss, PepFormula’s dedicated guide covers AOD-9604 alongside other relevant compounds.
AOD-9604 Dosage and Administration
The research-supported AOD-9604 dose is 300mcg per day for general use, rising to 500mcg–1mg per day in more advanced protocols. Administration is via subcutaneous injection, delivered 30 minutes before eating or training for optimal uptake.
AOD-9604 Dosage Chart
| Experience Level | Dose | Frequency | Duration |
|---|---|---|---|
| Beginner | 250–300mcg | Once daily, morning | 6–8 weeks |
| Intermediate | 400–500mcg | Once daily, morning | 10–12 weeks |
| Advanced | 500mcg–1mg | Once or twice daily | 12 weeks |
Timing and Administration
Morning administration on an empty stomach is the standard protocol across all clinical and research references. The rationale is straightforward: growth hormone secretion naturally peaks during fasting states, and AOD-9604 appears to work synergistically with this physiological pattern.
Some advanced protocols split the dose — for example, 250mcg in the morning and 250mcg pre-workout. This approach has theoretical support from pharmacokinetic data but has not been directly tested in controlled trials.
Injection site: Subcutaneous injection into the abdomen, lateral thigh, or flanks. Rotate sites daily to prevent localized tissue irritation. For a detailed breakdown of injection techniques, see the guide on how to inject peptides.
Cycle Length
Most protocols run 12 weeks, mirroring the duration used in clinical trials. A minimum of 4 weeks is needed to observe measurable body composition changes. After a 12-week cycle, a break of 4–8 weeks before resuming is standard practice.
Use the AOD-9604 dosage calculator on PepFormula to calculate your precise dose, injection volume, and reconstitution figures based on your vial concentration and target dose.
How to Reconstitute AOD-9604
AOD-9604 is supplied as a lyophilized (freeze-dried) white powder that must be reconstituted with bacteriostatic water before use. The reconstitution process is identical across most research peptides and takes under five minutes.
- Gather your materials: AOD-9604 vial (typically 2mg or 5mg), bacteriostatic water (BW), 1ml insulin syringes, alcohol swabs
- Wipe both vial septa with an alcohol swab and allow to air dry for 10 seconds
- Draw bacteriostatic water into the syringe — use 1ml BW per 2mg of peptide as a starting ratio (this gives 200mcg per 0.1ml drawn)
- Inject the BW slowly into the peptide vial, directing the stream against the glass wall rather than directly onto the powder to avoid foaming
- Do not shake — gently swirl until the powder is fully dissolved; the solution should be clear and colourless
- Label the vial with the date of reconstitution
- Store refrigerated at 2–8°C; use within 28 days of reconstitution
For a full walkthrough including dilution tables and syringe selection, read the guide on how to reconstitute peptides on PepFormula. For details on why bacteriostatic water is the correct diluent, see the bacteriostatic water explainer.
Proper storage is critical — AOD-9604 degrades rapidly when exposed to heat or light. Review how to store peptides to ensure your vials remain stable throughout your cycle.
AOD-9604 Side Effects
AOD-9604 has a well-characterized safety profile from human clinical trials, with most participants reporting no significant adverse effects. It is one of the better-studied peptides in terms of human tolerability data.
Reported side effects from clinical trials include:
- Mild injection site reactions (redness, transient swelling) — the most commonly reported event
- Headache — reported in a small subset of subjects, typically resolving within the first week of use
- Nausea — infrequent, more common with higher oral doses than injectable use
What does not appear to occur:
- Elevated IGF-1 levels — confirmed across multiple trials
- Blood glucose disruption or insulin resistance — confirmed across multiple trials
- Hypothalamic-pituitary-adrenal (HPA) axis suppression — no evidence of endogenous hormone disruption
- Androgenic or oestrogenic activity — none identified
The absence of IGF-1 elevation is significant because it rules out several mechanisms of concern associated with growth hormone misuse, including potential proliferative effects on existing abnormal cells.
At doses above 1mg/day, the benefit-to-effect ratio does not appear to improve meaningfully — clinical data found that 1mg/day outperformed 9mg/day in fat loss outcomes, suggesting a bell-curve dose-response relationship. Higher doses are not associated with proportionally greater fat loss and may increase side effect likelihood without benefit.
Is AOD-9604 Legal?
AOD-9604’s legal status varies significantly by country and intended use. The GRAS designation granted by the FDA in 2014 applies specifically to its use as a food additive or supplement ingredient, not as a pharmaceutical drug or injectable peptide.
United States: AOD-9604 is not FDA-approved as a drug. It is classified as a research chemical and can be legally purchased for laboratory research purposes. It cannot legally be sold as a dietary supplement for human consumption or prescribed by physicians outside of a compounding pharmacy context. Some compounding pharmacies have prepared AOD-9604 for patients under physician supervision, though FDA enforcement in this area has tightened since 2021.
United Kingdom: AOD-9604 is not a controlled substance under the Misuse of Drugs Act. It is legal to purchase for research purposes. It is not licensed as a medicine in the UK and cannot be marketed for human use.
Australia: AOD-9604 is listed as a Schedule 4 (Prescription Only) substance in Australia under the TGA’s scheduling framework. It cannot be legally purchased without a valid prescription. Given its Australian origins at Monash University, its regulatory status there has been closely monitored by the TGA.
Canada: Not a controlled substance but subject to Health Canada oversight as an unauthorized drug. Possession for personal research use sits in a regulatory grey area.
In all jurisdictions, AOD-9604 is not approved for human use as a pharmaceutical product. Anyone using it does so outside the scope of licensed medical practice, and legal status can change as regulatory bodies update their scheduling decisions.
Frequently Asked Questions
What is the correct AOD-9604 dosage for weight loss? The most evidence-supported AOD-9604 dosage for fat loss is 300mcg to 500mcg per day, administered subcutaneously in the morning on an empty stomach. The pivotal clinical trial used 1mg/day and demonstrated significant fat reduction over 12 weeks without metabolic side effects. Starting at 300mcg and titrating upward based on tolerance is the standard approach in research protocols.
How do I use an AOD-9604 dosage calculator? An AOD-9604 dosage calculator takes your vial size (in mg), your chosen dose (in mcg), and the volume of bacteriostatic water used to reconstitute the peptide, then outputs the precise injection volume in millilitres. For example, a 2mg vial reconstituted with 2ml of bacteriostatic water gives a concentration of 1000mcg/ml, meaning a 300mcg dose requires 0.3ml. The AOD-9604 dosage calculator on PepFormula handles all of these calculations automatically.
How long does it take for AOD-9604 to work? Most users and research subjects report noticeable changes in body composition beginning at weeks 4–6 of consistent daily administration. The clinical trial showing the most significant fat loss results ran for 12 weeks, which represents the evidence-supported minimum for a full treatment cycle. Changes are more pronounced when the peptide is combined with a structured caloric deficit and regular exercise.
Can AOD-9604 be stacked with other peptides? AOD-9604 is frequently combined with peptides such as BPC-157, CJC-1295, and Ipamorelin in research protocols. Because AOD-9604 does not elevate IGF-1 or affect the GHRH axis, it does not conflict pharmacologically with GHRP or GHRH-class peptides. The combination with CJC-1295 or Ipamorelin is used to support the natural GH pulse while AOD-9604 targets fat stores directly.
Does AOD-9604 affect muscle mass or testosterone? AOD-9604 has no known anabolic, androgenic, or oestrogenic activity. It does not affect testosterone levels, and clinical trials confirmed no impact on lean muscle mass — fat loss with AOD-9604 is tissue-selective. This is one of the primary pharmacological advantages of using a targeted hGH fragment rather than full-length growth hormone, which can cause water retention, joint pain, and insulin resistance at therapeutic doses.
Summary
AOD-9604 is one of the most rigorously studied research peptides in the fat loss category, with human clinical trial data confirming its lipolytic effects, IGF-1 neutrality, and absence of meaningful metabolic side effects. The optimal dose sits at 300mcg–1mg per day via subcutaneous injection, taken in the morning in a fasted state, across a 12-week cycle. Precision in reconstitution and dosing is essential — minor errors in concentration calculations translate directly to under- or over-dosing.
Use the AOD-9604 dosage calculator on PepFormula to calculate your exact injection volume based on your vial size, reconstitution volume, and target dose before starting any protocol.
This article is for informational purposes only. Always consult a healthcare professional before using any peptide compound. Peptides are research chemicals and their legal status varies by jurisdiction.
This article is for informational and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before using any peptide compound. Calculator results are mathematical estimates — verify all doses with a licensed clinician.